Considering mCRP as a significant contributor to the triggering of AD after stroke [14,30] and to the progression of neuroinflammation and loss of synaptic function in AD [14], effective treatments against it may be able to decrease poststroke AD cases and other diseases involving CRP activation. The gene discussed is CRP; the disease is Alzheimer disease.